THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program

Disclosure: J. Newell-Price: Consulting Fee; Self; HRA Pharmaceuticals, Diurnal, Novartis Pharmaceuticals, Recordati Rare Diseases, Crinetics. Grant Recipient; Self; Crinetics, Diurnal, HRA Pharmaceuticals, Novartis Pharmaceuticals, Recordati Rare Diseases. R. Pivonello: Consulting Fee; Self; Novart...

Descripción completa

Detalles Bibliográficos
Autores principales: Newell-Price, John, Pivonello, Rosario, Lacroix, André, Biller, Beverly M K, Feelders, Richard, Gadelha, Mônica, Bertherat, Jérôme, Belaya, Zhanna, Piacentini, Andrea, Pedroncelli, Alberto M, Fleseriu, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554774/
http://dx.doi.org/10.1210/jendso/bvad114.1118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554774/
http://dx.doi.org/10.1210/jendso/bvad114.1118

Ejemplares similares